Camber Pharmaceuticals is voluntarily recalling all unexpired lots of Valsartan tablets, USP, 40mg, 80mg, 160mg and 320mg to the hospital, retail and consumer level, as a precautionary measure.
Perrigo, a global healthcare company, said that its board of directors approved a plan to separate its Prescription Pharmaceuticals (Rx) business following a previously announced strategic portfolio review.
Abzena said that it has completed the GMP drug substance manufacture of an ABZENA Inside product that was originally humanized using the company’s Composite Human Antibody platform.
Sun Pharmaceutical Industries has launched Kapspargo Sprinkle (metoprolol succinate) extended-release capsules in the US, for the treatment of hypertension (to lower blood pressure), angina pectoris (chest pain), and heart failure.
LEO Pharma, a Danish firm focused on developing drugs for dermatologic and thrombotic patients, has agreed to acquire the global prescription dermatology business of Bayer for an undisclosed price.
Biopharmaceutical firm Amgen has broken ground on its next-generation biomanufacturing facility in Rhode Island, US.
Pfizer has unveiled plans to invest $465m for the development of a new sterile injectable pharmaceutical production facility in Michigan, US.
UK-based life sciences group Abzena has signed GMP manufacturing and bioconjugation agreements with Australia-based Telix Pharmaceuticals.
Starpharma and Mundipharma have signed a licence agreement for the sales and marketing rights to VivaGel BV for 43 countries in Europe, Russia, the Commonwealth of Independent States (CIS) and the balance of countries in Latin America.
Takeda Pharmaceutical has agreed to divest its its majority shareholding of 51.34% in Guangdong Techpool Bio-Pharma (Techpool), a China-based firm focused on urinary protein biopharmaceuticals and production of biopharmaceuticals in critical care, to its joint venture (JV) partners for $280m.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.